Suppr超能文献

脑脊液蛋白质组学定义常染色体显性阿尔茨海默病的自然史。

Cerebrospinal fluid proteomics define the natural history of autosomal dominant Alzheimer's disease.

机构信息

Goizueta Alzheimer's Disease Research Center, Emory University School of Medicine, Atlanta, GA, USA.

Department of Neurology, Emory University School of Medicine, Atlanta, GA, USA.

出版信息

Nat Med. 2023 Aug;29(8):1979-1988. doi: 10.1038/s41591-023-02476-4. Epub 2023 Aug 7.

Abstract

Alzheimer's disease (AD) pathology develops many years before the onset of cognitive symptoms. Two pathological processes-aggregation of the amyloid-β (Aβ) peptide into plaques and the microtubule protein tau into neurofibrillary tangles (NFTs)-are hallmarks of the disease. However, other pathological brain processes are thought to be key disease mediators of Aβ plaque and NFT pathology. How these additional pathologies evolve over the course of the disease is currently unknown. Here we show that proteomic measurements in autosomal dominant AD cerebrospinal fluid (CSF) linked to brain protein coexpression can be used to characterize the evolution of AD pathology over a timescale spanning six decades. SMOC1 and SPON1 proteins associated with Aβ plaques were elevated in AD CSF nearly 30 years before the onset of symptoms, followed by changes in synaptic proteins, metabolic proteins, axonal proteins, inflammatory proteins and finally decreases in neurosecretory proteins. The proteome discriminated mutation carriers from noncarriers before symptom onset as well or better than Aβ and tau measures. Our results highlight the multifaceted landscape of AD pathophysiology and its temporal evolution. Such knowledge will be critical for developing precision therapeutic interventions and biomarkers for AD beyond those associated with Aβ and tau.

摘要

阿尔茨海默病(AD)的病理变化在认知症状出现前多年就已开始。两种病理过程——β淀粉样蛋白(Aβ)肽聚集成斑块和微管蛋白 tau 聚集成神经原纤维缠结(NFTs)——是该疾病的标志。然而,人们认为其他病理脑过程是 Aβ斑块和 NFT 病理的关键疾病介质。目前尚不清楚这些额外的病理过程在疾病过程中是如何演变的。在这里,我们展示了与脑蛋白共表达相关的常染色体显性 AD 脑脊液(CSF)中的蛋白质组学测量可以用于描述 AD 病理学在跨越六十年的时间尺度上的演变。与 Aβ斑块相关的 SMOC1 和 SPON1 蛋白在症状出现前近 30 年就出现在 AD CSF 中,随后是突触蛋白、代谢蛋白、轴突蛋白、炎症蛋白和最后是神经分泌蛋白的变化。该蛋白质组在症状出现前就能够区分突变携带者和非携带者,其效果与 Aβ和 tau 测量一样好,甚至更好。我们的结果突出了 AD 病理生理学及其时间演变的多方面性。这种知识对于开发超越 Aβ和 tau 的 AD 精准治疗干预措施和生物标志物至关重要。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bf58/10427428/f59c8d45901d/41591_2023_2476_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验